Balchem Corporation Reports Third Quarter 2026 Financial Results
Balchem reported record Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and GAAP net earnings of $46.7 million, up 16.0%. All three segments grew, led by Animal Nutrition and Health (+11.7% sales, +82.8% operating earnings), while gross margin expanded 70 basis points to 36.4%. Adjusted EBITDA rose 12.4% to $80.3 million with free cash flow of $57.9 million.
Key figures
- Eps
- $1.46 GAAP / $1.57 adjusted
- Revenue
- 290700000
- Guidance
- No quantified guidance given; management expressed confidence in long-term growth outlook
- Revenue Yoy
- 8.6%
- Fcf
- 57909000
- Net debt
- 57700000
- Buyback q3
- 27400000
- Buyback ttm
- $127 million (approx.)
- Net earnings
- 46728000
- Adjusted ebitda
- 80297000
- Gross margin pct
- 36.4%
- Net earnings yoy
- 16.0%
- Adjusted ebitda yoy
- 12.4%
- Human nutrition sales
- $188.2 million (+8.1%)
- Animal nutrition sales
- $63.0 million (+11.7%)
- Gross margin pct prior
- 35.7%
- Net debt leverage ratio
- 0.2x
- Specialty products sales
- $37.3 million (+4.5%)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.